ArticleDigestive diseases and sciences2024
Temporal Trends of Inflammatory Bowel Diseases in Taiwan from 2016 to 2020: A Population-Based Study.
Article in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Taiwan practical consensus for evaluation and management of small-bowel bleeding.Journal of the Chinese Medical Association : JCMA · 2026Guideline
- Guselkumab in East Asians With Moderate-to-Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies.Journal of gastroenterology and hepatology · 2025Trial
- Epidemiology of diagnosed inflammatory bowel disease in Taiwan population from 2011 to 2021: a population-based study.BMC gastroenterology · 2026Article
- Preventive Effect ofNutrients · 2026Article
- Jaundice marks immunoglobulin G4-related cholangitis in type 1 autoimmune pancreatitis patients.Therapeutic advances in gastroenterology · 2026Article
- Comparative risks of inflammatory bowel disease in patients with type 2 diabetes mellitus treated with SGLT-2 inhibitors versus DPP-4 inhibitors: a real-world nationwide cohort study.International journal of clinical pharmacy · 2025Article
- Combining Network Pharmacology, Molecular Docking, and Integrative Studies to Explore the Mechanism ofFood science & nutrition · 2025Article
- Elderly-onset inflammatory bowel disease in Asia: clinical characteristics and therapeutic strategies.Intestinal research · 2025Review
- Efficacy and safety of Risankizumab for moderate-to-severe Crohn's disease: first Asian real-world data (STAR trial).Therapeutic advances in gastroenterology · 2025Article
- Crohn's disease in coastal China: epidemiological profile and determinants of diagnostic delay in the Yancheng cohort.Frontiers in physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are scanty population-based studies investigating the incidence and prevalence rates of inflammatory bowel disease (IBD) in Taiwan.
aimsThis study aimed to estimate the nationwide prevalence and incidence of IBD and identify its noticeable trends in Taiwan between 2016 and 2020.
methodsA retrospective study by analyzing the data from the National Health Insurance Research Database of Taiwan.
resultsA total of 2595 patients with catastrophic IBD illness were registered from 2016 to 2020 in Taiwan (CD, 880; UC, 1715). The male-to-female ratio in the study sample was 1.83:1 for CD and 1.69:1 for UC. The median age of those registered with CD and UC was 37 and 47 years, respectively. The incidence rate of CD was 0.65 per 100,000 persons in 2016 and it was increased to 0.81 per 100,000 persons in 2020. The incidence rate of UC was 1.16 per 100,000 persons in 2016 and it was increased to 1.53 in 2020. Overall, the incidence of IBD was increase from 1.81 per 100,000 persons to 2.34 per 100,000 persons between 2016 and 2020. Overall, the prevalence rates of IBD was increase from 14.95 per 100,000 persons to 20.02 per 100,000 persons between 2016 and 2020.
conclusionThe epidemiological stages of IBD in Taiwan was considered in the acceleration in incidence stage, during which incidence rises and prevalence is relatively low. Understanding these geographical differences is important for the rising global burden of IBD.
Indexed as
Identifiers
38949750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.